Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crescita Therpeutc J (TSE:CTX)
TSX:CTX
Holding TSE:CTX?
Track your performance easily
CTX Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.36 - C$0.70
Previous CloseC$0.55
Volume1.55K
Average Volume (3M)23.31K
Market Cap
C$10.51M
Enterprise ValueC$3.00M
Total Cash (Recent Filing)C$8.44M
Total Debt (Recent Filing)C$926.00K
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Mar 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding19,441,171
10 Day Avg. Volume5,124
30 Day Avg. Volume23,309
Standard Deviation0.15
R-Squared0.25
Alpha-0.00982
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.66
Price to Sales (P/S)0.61
Price to Cash Flow (P/CF)6.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Crescita Therpeutc News
PremiumCompany Announcements
Crescita Therapeutics Sees Strong Q3 Revenue GrowthPremiumCompany Announcements
Crescita Therapeutics Positions for Growth Amid Q2 Challenges
PremiumCompany Announcements
Crescita Therapeutics Secures Lucrative Manufacturing DealPremiumCompany Announcements
Crescita Secures Exclusive Manufacturing Deal in Healthcare
PremiumCompany Announcements
Crescita Therapeutics to Distribute Revolutionary Injection Device
PremiumCompany Announcements
Crescita Therapeutics Expands with Occy Assets Buy
PremiumCompany Announcements
Crescita Therapeutics Boosts Skincare Portfolio
PremiumCompany Announcements
Crescita Shareholders Back Directors and Incentive PlanOptions Prices
Currently, No data available
---
Ownership Overview
5.19%
Insiders
― Other Institutional Investors
94.81% Public Companies and
Individual Investors
CTX FAQ
What was Crescita Therpeutc J’s price range in the past 12 months?
Crescita Therpeutc J lowest stock price was C$0.36 and its highest was C$0.70 in the past 12 months.
What is Crescita Therpeutc J’s market cap?
Currently, no data Available
When is Crescita Therpeutc J’s upcoming earnings report date?
Crescita Therpeutc J’s upcoming earnings report date is Mar 19, 2025 which is in 86 days.
How were Crescita Therpeutc J’s earnings last quarter?
Crescita Therpeutc J released its earnings results on Nov 06, 2024. The company reported -C$0.054 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.054.
Is Crescita Therpeutc J overvalued?
According to Wall Street analysts Crescita Therpeutc J’s price is currently Overvalued.
Does Crescita Therpeutc J pay dividends?
Crescita Therpeutc J does not currently pay dividends.
What is Crescita Therpeutc J’s EPS estimate?
Crescita Therpeutc J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Crescita Therpeutc J have?
Crescita Therpeutc J has 19,118,042 shares outstanding.
What happened to Crescita Therpeutc J’s price movement after its last earnings report?
Crescita Therpeutc J reported an EPS of -C$0.054 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.695%.
Which hedge fund is a major shareholder of Crescita Therpeutc J?
Currently, no hedge funds are holding shares in TSE:CTX
---
Crescita Therpeutc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
-15.57%
Trailing 12-Months
Asset Growth
-10.59%
Trailing 12-Months
Company Description
Crescita Therpeutc J
Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.
---
Technical Analysis
---